Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Net Income towards Common Stockholders (2020 - 2023)

Historic Net Income towards Common Stockholders for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to -$5.4 million.

  • Candel Therapeutics' Net Income towards Common Stockholders rose 3160.63% to -$5.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$33.7 million, marking a year-over-year increase of 424.87%. This contributed to the annual value of -$30.2 million for FY2024, which is 1044.05% up from last year.
  • Latest data reveals that Candel Therapeutics reported Net Income towards Common Stockholders of -$5.4 million as of Q4 2023, which was up 3160.63% from -$9.0 million recorded in Q3 2023.
  • Over the past 5 years, Candel Therapeutics' Net Income towards Common Stockholders peaked at -$2.5 million during Q2 2020, and registered a low of -$9.8 million during Q2 2023.
  • For the 4-year period, Candel Therapeutics' Net Income towards Common Stockholders averaged around -$7.1 million, with its median value being -$7.9 million (2022).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 19700.89% in 2021, then surged by 3160.63% in 2023.
  • Quarter analysis of 4 years shows Candel Therapeutics' Net Income towards Common Stockholders stood at -$6.1 million in 2020, then decreased by 27.57% to -$7.8 million in 2021, then fell by 1.6% to -$7.9 million in 2022, then skyrocketed by 31.61% to -$5.4 million in 2023.
  • Its Net Income towards Common Stockholders was -$5.4 million in Q4 2023, compared to -$9.0 million in Q3 2023 and -$9.8 million in Q2 2023.